OTCMKTS:BIOAF - biOasis Technologies Stock Price, News, & Analysis

$0.21
-0.02 (-8.70 %)
(As of 06/19/2019 08:48 AM ET)
Today's Range
$0.1852
Now: $0.21
$0.2162
50-Day Range
$0.20
MA: $0.23
$0.2710
52-Week Range
$0.1852
Now: $0.21
$0.5301
Volume2,090 shs
Average Volume2,062 shs
Market Capitalization$13.27 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.11
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics and imaging agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical needs, including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain metastases, glioblastomas, and neurodegenerative diseases. Bioasis Technologies Inc. has a collaborative research agreement with CQDM and Brain Canada to perform research on the delivery of therapeutic compounds across the BBB; and a strategic collaboration with BIOAGILYTIX for the development and validation of bioanalytical methods to support the xB3 TM-001 program, as well with WuXi Biologics (Hong Kong) Limited for the development and manufacturing of xB3-001 to treat cancer. The company was incorporated in 2006 and is headquartered in Guilford, Connecticut.

Industry, Sector and Symbol

Industry Drugs, proprietaries, & sundries
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BIOAF
CUSIPN/A
CIKN/A
Phone203-390-7395

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$0.01 per share

Profitability

Net Income$-4,120,000.00

Miscellaneous

EmployeesN/A
Market Cap$13.27 million
Next Earnings Date7/29/2019 (Estimated)
OptionableNot Optionable

Receive BIOAF News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOAF and its competitors with MarketBeat's FREE daily newsletter.

biOasis Technologies (OTCMKTS:BIOAF) Frequently Asked Questions

What is biOasis Technologies' stock symbol?

biOasis Technologies trades on the OTCMKTS under the ticker symbol "BIOAF."

When is biOasis Technologies' next earnings date?

biOasis Technologies is scheduled to release their next quarterly earnings announcement on Monday, July 29th 2019. View Earnings Estimates for biOasis Technologies.

Has biOasis Technologies been receiving favorable news coverage?

Media headlines about BIOAF stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. biOasis Technologies earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the stock's share price in the near future. View News Stories for biOasis Technologies.

Who are some of biOasis Technologies' key competitors?

What other stocks do shareholders of biOasis Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other biOasis Technologies investors own include Boot Barn (BOOT), JPMorgan Chase & Co. (JPM), Canopy Growth (CGC), A10 Networks (ATEN), Allergan (AGN), Shotspotter (SSTI), Citius Pharmaceuticals (CTXR), Cronos Group (CRON), Ballard Power Systems (BLDP) and Atomera (ATOM).

Who are biOasis Technologies' key executives?

biOasis Technologies' management team includes the folowing people:
  • Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE, Exec. Chair, CEO & Pres (Age 61)
  • Ms. Christine Antalik, Chief Financial Officer (Age 48)
  • Mr. Graeme Dick, Director of Investor Relations
  • Mr. Kim Elton, Director of Marketing
  • Mr. Doug Williams MBA, Exec. VP & Chief Bus. Officer

How do I buy shares of biOasis Technologies?

Shares of BIOAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is biOasis Technologies' stock price today?

One share of BIOAF stock can currently be purchased for approximately $0.21.

How big of a company is biOasis Technologies?

biOasis Technologies has a market capitalization of $13.27 million and generates $460,000.00 in revenue each year. View Additional Information About biOasis Technologies.

What is biOasis Technologies' official website?

The official website for biOasis Technologies is http://www.bioasis.us/.

How can I contact biOasis Technologies?

biOasis Technologies' mailing address is 14 Water Street, Guilford CT, 06437. The company can be reached via phone at 203-390-7395 or via email at [email protected]


MarketBeat Community Rating for biOasis Technologies (OTCMKTS BIOAF)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  47 (Thanks for Voting!)
Underperform Votes:  65 (Thanks for Voting!)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about biOasis Technologies and other stocks. Vote "Outperform" if you believe BIOAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2019 by MarketBeat.com Staff

Featured Article: Return On Assets

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel